PRPO
Precipio, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-54/100
Last price
23.45
▼ 0.55 (2.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
24.00
Day high
24.27
Day low
23.30
Volume
18.16K
Market cap
$41.98M
P/E (TTM)
—
52W range
16.40 – 33.63
Trailing performance
Returnvs SPY
1W
-0.55%
-2.5%
1M
-14.42%
-15.6%
3M
-10.22%
-14.7%
6M
-17.72%
-35.9%
YTD
+2.05%
-12.2%
1Y
+12.85%
-3.6%
3Y
+318.00%
+235.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRPO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-2.07K
Net selling
Buy transactions
7
1.97K shares
Sell transactions
2
4.03K shares
Net transactions
+9
Buys less sells
Sell : buy shares
2.1 : 1
Mixed
Insider-held shares
226.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 15, 26 | COHEN DAVID SETH Director |
STOCK | 520 | $13.13K | Direct |
| Jul 15, 26 | COSSMAN JEFFREY M.D. Director |
STOCK | 416 | $10.50K | Direct |
| Jul 15, 26 | VALAURI CHRISTINA RIZOPOULOS Director |
STOCK | 108 | $2.73K | Direct |
| May 21, 26 | SANDBERG RICHARD A Director |
SELL | 900 | $22.52K | Indirect |
| May 20, 26 | SANDBERG RICHARD A Director |
SELL | 3.13K | $77.78K | |
| Apr 15, 26 | COHEN DAVID SETH Director |
STOCK | 445 | $13.12K | Direct |
| Apr 15, 26 | COSSMAN JEFFREY M.D. Director |
STOCK | 365 | $10.76K | Direct |
| Apr 15, 26 | VALAURI CHRISTINA RIZOPOULOS Director |
STOCK | 93 | $2.74K | Direct |
| Apr 1, 26 | SABET AHMED ZAKI Chief Operating Officer |
BUY | 19 | $531 | Direct |
| Jan 15, 26 | LAPORTE KATHLEEN D Director |
STOCK | 520 | $12.48K | Direct |
| Jan 15, 26 | COHEN DAVID SETH Director |
STOCK | 546 | $13.10K | Direct |
| Jan 15, 26 | COSSMAN JEFFREY M.D. Director |
STOCK | 437 | $10.49K | Direct |
| Jan 15, 26 | VALAURI CHRISTINA RIZOPOULOS Director |
STOCK | 406 | $9.74K | Direct |
| Jan 2, 26 | SABET AHMED ZAKI Chief Operating Officer |
BUY | 20 | $468 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDREWS RONALD ASBURY |
Director | 15.71K | Stock Award(Grant) |
COHEN DAVID SETH |
Director | 55.20K | Stock Award(Grant) |
COSSMAN JEFFREY M.D. |
Director | 16.55K | Stock Award(Grant) |
LAPORTE KATHLEEN D |
Director | 7.38K | Stock Award(Grant) |
SABET AHMED ZAKI |
Chief Operating Officer | 1.03K | Purchase |
SANDBERG RICHARD A |
Director | — | Sale |
VALAURI CHRISTINA RIZOPOULOS |
Director | 5.63K | Stock Award(Grant) |
Fundamentals
Market cap$41.98M
Enterprise value$42.49M
Revenue (TTM)$27.20M
Gross profit$12.00M
EBITDA$-129.00K
Net income$-1.22M
EPS (TTM)$-0.62
Free cash flow$1.35M
Total cash$3.08M
Total debt$3.59M
Book value / share$8.25
Shares outstanding1.79M
Float1.41M
Short % of float4.53%
Dividend yield0.00%
Beta (5Y)1.30
Valuation & profitability ratios
Trailing P/E—
Forward P/E60.13
PEG ratio—
Price / sales—
Price / book2.84
EV / revenue1.56
EV / EBITDA-329.40
Gross margin44.11%
Operating margin-8.53%
Profit margin-4.47%
Return on equity-8.98%
Return on assets-4.81%
Debt / equity24.31
Current ratio1.77
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $24.05M | $18.53M | $15.20M | $9.41M | +29.8% |
| Operating revenue | $24.25M | $18.58M | $15.41M | $8.42M | +30.5% |
| Cost of revenue | $13.34M | $10.97M | $9.18M | $6.90M | +21.6% |
| Gross profit | $10.71M | $7.56M | $6.02M | $2.51M | +41.6% |
| Total operating expense | $11.91M | $11.78M | $13.64M | $15.31M | +1.1% |
| Net interest income | -$73.00K | -$74.00K | -$18.00K | -$12.00K | +1.4% |
| Pre-tax income | -$363.00K | -$4.29M | -$5.85M | -$12.18M | +91.5% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$363.00K | -$4.29M | -$5.85M | -$12.20M | +91.5% |
| Net income to common | -$363.00K | -$4.29M | -$5.85M | -$12.20M | +91.5% |
| Basic EPS | -0.23 | -2.93 | -4.51 | -10.73 | +92.2% |
| Diluted EPS | -0.23 | -2.93 | -4.51 | -10.73 | +92.2% |
| EBIT | -$290.00K | -$4.22M | -$5.83M | -$12.17M | +93.1% |
| EBITDA | $1.46M | -$2.70M | -$4.32M | -$10.65M | +154.1% |
| Basic shares | 1.61M | 1.47M | 1.30M | 1.14M | +9.5% |
| Diluted shares | 1.61M | 1.47M | 1.30M | 1.14M | +9.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $2.65M | $1.39M | $1.50M | $3.44M | +90.9% |
| Cash & short-term investments | $2.65M | $1.39M | $1.50M | $3.44M | +90.9% |
| Accounts receivable | $1.98M | $799.00K | $1.30M | $1.04M | +148.3% |
| Inventory | $935.00K | $724.00K | $384.00K | $708.00K | +29.1% |
| Total current assets | $6.04M | $3.45M | $3.68M | $5.71M | +75.0% |
| Property, plant & equipment | $4.29M | $1.63M | $1.52M | $1.90M | +163.2% |
| Goodwill & intangibles | $10.92M | $11.87M | $12.82M | $13.77M | -8.0% |
| Total assets | $21.32M | $17.00M | $18.10M | $21.50M | +25.4% |
| Total current liabilities | $3.75M | $4.27M | $3.14M | $4.36M | -12.2% |
| Current debt | $30.00K | $297.00K | $235.00K | $255.00K | -89.9% |
| Long-term debt | $47.00K | $77.00K | $106.00K | $134.00K | -39.0% |
| Total debt | $3.65M | $1.25M | $1.12M | $1.39M | +191.5% |
| Total liabilities | $6.76M | $4.90M | $3.67M | $5.14M | +37.8% |
| Retained earnings | -$102.80M | -$102.44M | -$98.15M | -$92.30M | -0.4% |
| Shareholder equity | $14.56M | $12.09M | $14.43M | $16.30M | +20.4% |
| Working capital | $2.29M | -$820.00K | $541.00K | $1.35M | +378.9% |
| Net tangible assets | $3.64M | $225.00K | $1.61M | $2.53M | +1,518.7% |
| Shares issued | 1.78M | 1.49M | 1.42M | 1.14M | +19.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$363.00K | -$4.29M | -$5.85M | -$12.18M | +91.5% |
| Depreciation & amortisation | $1.75M | $1.51M | $1.52M | $1.52M | +15.8% |
| Stock-based compensation | $1.45M | $1.88M | $1.74M | $3.80M | -22.7% |
| Change in working capital | -$2.17M | $1.27M | $606.00K | -$643.00K | -270.8% |
| Capital expenditure | -$326.00K | -$223.00K | -$126.00K | -$277.00K | -46.2% |
| Investing cash flow | -$326.00K | -$223.00K | -$126.00K | -$277.00K | -46.2% |
| Financing cash flow | $903.00K | -$329.00K | $1.74M | -$225.00K | +374.5% |
| Free cash flow | $359.00K | $216.00K | -$3.69M | -$8.00M | +66.2% |
| End cash position | $2.65M | $1.39M | $1.50M | $3.44M | +90.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $7.02M | $6.71M | $6.70M | $6.77M | $5.65M | — | +4.6% |
| Operating revenue | $7.02M | $6.96M | $6.82M | $6.88M | $5.63M | — | +0.9% |
| Cost of revenue | $3.88M | $3.99M | $3.57M | $3.76M | $3.23M | — | -2.5% |
| Gross profit | $3.14M | $2.73M | $3.13M | $3.00M | $2.43M | — | +15.1% |
| Selling, general & admin | — | — | — | — | -$789.00K | — | — |
| Total operating expense | $3.73M | $4.15M | $2.59M | $3.07M | $2.46M | — | -10.1% |
| Operating income | -$599.00K | -$1.43M | $542.00K | -$61.00K | -$824.00K | — | +58.1% |
| Net interest income | -$9.00K | -$15.00K | -$16.00K | -$9.00K | -$23.00K | — | +40.0% |
| Pre-tax income | -$219.00K | -$1.44M | $526.00K | -$79.00K | $74.00K | — | +84.8% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$219.00K | -$1.44M | $526.00K | -$79.00K | $74.00K | — | +84.8% |
| Net income to common | -$219.00K | -$1.44M | $526.00K | -$79.00K | $74.00K | — | +84.8% |
| Basic EPS | -0.12 | -0.81 | — | -0.05 | 0.05 | -0.59 | +85.2% |
| Diluted EPS | -0.12 | -0.81 | — | -0.05 | 0.05 | -0.59 | +85.2% |
| EBIT | -$210.00K | -$1.43M | $542.00K | -$70.00K | $97.00K | — | +85.3% |
| EBITDA | $259.00K | -$971.00K | $1.02M | $367.00K | $519.00K | — | +126.7% |
| Basic shares | 1.79M | 1.78M | — | 1.64M | 1.51M | 1.50M | +0.2% |
| Diluted shares | 1.79M | 1.78M | — | 1.64M | 1.60M | 1.50M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.08M | $2.60M | $2.65M | $2.31M | $1.13M | +18.1% |
| Cash & short-term investments | $3.08M | $2.60M | $2.65M | $2.31M | $1.13M | +18.1% |
| Accounts receivable | $2.28M | $1.99M | $1.98M | $1.96M | $1.49M | +14.6% |
| Inventory | $776.00K | $870.00K | $935.00K | $788.00K | $1.06M | -10.8% |
| Total current assets | $6.54M | $5.93M | $6.04M | $5.67M | $4.05M | +10.2% |
| Property, plant & equipment | $4.29M | $4.12M | $4.29M | $4.26M | $3.31M | +4.0% |
| Goodwill & intangibles | $10.44M | $10.68M | $10.92M | $11.16M | $11.39M | -2.2% |
| Total assets | $21.32M | $20.80M | $21.32M | $21.15M | $18.82M | +2.5% |
| Total current liabilities | $3.70M | $3.81M | $3.75M | $4.45M | $4.35M | -2.9% |
| Current debt | $73.00K | $30.00K | $30.00K | $30.00K | $29.00K | +143.3% |
| Long-term debt | $252.00K | $40.00K | $47.00K | $55.00K | $62.00K | +530.0% |
| Total debt | $3.59M | $3.49M | $3.65M | $3.56M | $2.61M | +2.7% |
| Total liabilities | $6.56M | $6.64M | $6.76M | $7.40M | $6.53M | -1.1% |
| Retained earnings | -$104.47M | -$104.25M | -$102.80M | -$103.33M | -$103.25M | -0.2% |
| Shareholder equity | $14.76M | $14.17M | $14.56M | $13.75M | $12.29M | +4.2% |
| Working capital | $2.84M | $2.12M | $2.29M | $1.22M | -$300.00K | +33.6% |
| Net tangible assets | $4.31M | $3.48M | $3.64M | $2.59M | $894.00K | +23.8% |
| Shares issued | 1.79M | 1.78M | 1.78M | 1.75M | 1.52M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$219.00K | -$1.44M | $526.00K | -$79.00K | $74.00K | +84.8% |
| Depreciation & amortisation | $469.00K | $457.00K | $476.00K | $437.00K | $422.00K | +2.6% |
| Stock-based compensation | $767.00K | $993.00K | $346.00K | $232.00K | $449.00K | -22.8% |
| Change in working capital | -$391.00K | -$247.00K | -$925.00K | -$729.00K | -$499.00K | -58.3% |
| Operating cash flow | $660.00K | $64.00K | $366.00K | $10.00K | $353.00K | +931.3% |
| Capital expenditure | -$132.00K | -$50.00K | -$75.00K | -$54.00K | -$59.00K | -164.0% |
| Investing cash flow | -$132.00K | -$50.00K | -$75.00K | -$54.00K | -$59.00K | -164.0% |
| Financing cash flow | -$57.00K | -$61.00K | $55.00K | $1.22M | -$181.00K | +6.6% |
| Free cash flow | $528.00K | $14.00K | $291.00K | -$44.00K | $294.00K | +3,671.4% |
| End cash position | $3.08M | $2.60M | $2.65M | $2.31M | $1.13M | +18.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2023 | -1.40 | -1.04 | +25.7% |
| Jun 2023 | -2.00 | -1.80 | +10.0% |
| Mar 2023 | -2.60 | -2.60 | 0.0% |
| Dec 2022 | -2.80 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders12.63%
Held by institutions17.71%
Institutions holding22
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
23.66
-0.90% from price
SMA 20
25.17
-6.85% from price
SMA 50
25.43
-7.78% from price
SMA 100
24.63
-4.81% from price
SMA 200
25.22
-7.01% from price
EMA 12
24.18
-3.02% from price
EMA 26
25.03
-6.31% from price
EMA 50
25.28
-7.23% from price
RSI (14)
40.6
Neutral
MACD (12,26,9)
-0.85
Hist -0.24
ATR (14)
1.18
5.03% of price
Realised vol 30D
49.9%
Annualised
Bollinger upper
28.34
20, 2σ
Bollinger lower
22.00
20, 2σ
50 / 200 cross
Golden
25.43 vs 25.22
Trend bias
Below 200
-7.01%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.37
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
49.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.5%
Peak to trough
Max drawdown 5Y
-91.7%
Peak to trough
ATR 14
1.18
5.03% of price
Beta (reported)
1.30
5Y monthly, from filing
Short interest
Shares short
73.78K
Prior 51.53K
Change vs prior
+43.2%
Shorts adding
% of float
4.53%
Normal
% of shares out
4.12%
Against total outstanding
Days to cover
0.4
Liquid
Float
1.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateApr 29, 2019
Last split1:20
Split dateSep 22, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-06-15
Periodic Financial Reports
10-Q · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-05-06
Annual Report to Shareholders
ARS · 2026-04-28
Periodic Financial Reports
10-K · 2026-03-30
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Zacks · 15d ago
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
Zacks · 26d ago
Top Research Reports for Goldman Sachs, RTX & Abbott
Zacks · 26d ago
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Zacks · 44d ago
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
Zacks · 47d ago
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
GuruFocus.com · 47d ago
Precipio, Inc. Q2 2026 Earnings Call Summary
Moby · 53d ago
Precipio Announces Q2-2026 Financial Results
GlobeNewswire · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.